This is a routine annual meeting with no material financial or strategic implications. Traders should note that the company is following standard corporate governance practices, but there are no new financial disclosures or strategic announcements to act upon.
ELAN drugs
ELAN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $23.60entry
- T+1 · 7mo ago −0.93%α −1.50% · $23.38
- T+5 · 7mo ago −1.65%α −5.17% · $23.21
- T+20 · 7mo ago −2.57%α −11.12% · $22.99
- T+60 · 4mo ago +5.95%α −4.23% · $25.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elanco Animal Health Inc. (ELAN) is holding its 2026 Annual Meeting of Shareholders, where shareholders will vote on the election of five directors, ratification of the independent auditor, and an advisory vote on executive compensation. This is a routine annual shareholder meeting with no material financial or strategic announcements.
Key Financial Metrics
Key Facts
- ELAN is holding its 2026 Annual Meeting of Shareholders
- Shareholders will vote on the election of five directors
- Shareholders will vote on ratifying the appointment of Ernst & Young LLP as the independent auditor
- Shareholders will vote on an advisory vote on executive compensation
- The meeting is scheduled for May 21, 2026, with voting due by May 20, 2026
Financial Impact
No material financial impact
Risk Factors
- No immediate financial risks identified
- No strategic risks identified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001739104-26-000018 |
| Document: 0001739104-26-000018-index-headers.html | 0001739104-26-000018 |
| Document: 0001739104-26-000018-index.html | 0001739104-26-000018 |
| Document: 0001739104-26-000018.txt | 0001739104-26-000018 |
Track record
19 reports on ELAN
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers